Health Economics›Malignant solid neoplasm ERBB3-mutated›All lines of therapy

All lines of therapy

Malignant solid neoplasm ERBB3-mutated · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Neratinib monotherapy Variant #02	ERBB3	R 19 339	28d	—	—	~52	~R 1 005 645 PFS proxy · indirect	1

1 of 1 regimen shown